Clinical trials: Relapsed/Refractory T-cell Lymphoma
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00818961
- Testing
- alemtuzumab, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northside Hospital, Inc.
Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 chimeric antigen receptor T-cell (CAR T-cell) therapy for…
- Conditions
- Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma
- Trial name
- NCT05075603
- Testing
- Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- NeoImmuneTech
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
RATIONALE: Methadone, morphine, or oxycodone may help relieve pain caused by cancer. It is not yet known whether methadone is more effective than morphine or oxycodone in treating pain in patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00726830
- Testing
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
This is a single-arm, multi-center, open-label phase 2 study of the SINE™ compound selinexor given orally to patients with relapsed or refractory PTCL or CTCL.
- Trial name
- NCT02314247
- Testing
- Selinexor
- Where
- 5 sites in Australia, Singapore
- Volunteers
- 16 people
- Sponsor
- Karyopharm Therapeutics Inc
T Cell Lymphoma
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.
- Trial name
- NCT03770000
- Testing
- Tenalisib, Romidepsin
- Where
- 15 sites in United States
- Volunteers
- 33 people
- Sponsor
- Rhizen Pharmaceuticals SA
Chronic Myeloproliferative Disorders, Leukemia
Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
RATIONALE: Giving chemotherapy, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- LCCC0510 (NCT00448357)
- Testing
- rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with vincristine in treating patients with T-cell or B-cell acute lymphoblastic leukemia that has come back…
- Conditions
- Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Recurrent T Acute Lymphoblastic Leukemia
- Trial name
- NCT03504644
- Testing
- Biospecimen Collection, Computed Tomography, Lumbar Puncture
- Where
- 170 sites in United States, Puerto Rico
- Volunteers
- 40 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
This research study is studying the combination of anakinra and axicabtagene ciloleucel to reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic toxicities with relapsed or refractory…
- Conditions
- Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Neurotoxicity
- Trial name
- NCT04150913
- Testing
- Anakinra, Axicabtagene Ciloleucel
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
Lymphoma, Lymphoma, B-Cell
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
This research study combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been…
- Conditions
- Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders
- Trial name
- NCT03696784
- Testing
- iC9-CAR19 T cells, Bendamustine, Fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lymphoma, T-Cell, Peripheral
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
This is a multicenter, single-arm, open label, study consisting of two cohorts. Cohort 2 explores the combination of copanlisib and pembrolizumab in patients with relapsed or refractory NKTCL, who have received at least 1 prior…
- Trial name
- NCT02535247
- Testing
- MK-3475, Copanlisib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Fox Chase Cancer Center
Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
- Trial name
- NCT00866047
- Testing
- brentuximab vedotin
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 58 people
- Sponsor
- Seagen Inc.
T Cell Non-Hodgkin Lymphoma
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
The purpose of this research study is to evaluate the overall response rate to imatinib mesylate in participants with relapsed or refractory T cell non-Hodgkin's lymphoma.
- Trial name
- NCT00684411
- Testing
- Imatinib mesylate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
This phase II trial studies the side effects and best dose of anakinra and to see how well it works in reducing side effects (toxicity) associated with a CAR-T cell treatment called axicabtagene ciloleucel in patients with large…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Trial name
- NCT04432506
- Testing
- Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
This is a modular dose confirmation and expansion study. The core study design is to assess the efficacy of AZD4573, administered as monotherapy or combination therapy, to participants with either r/r PTCL or r/r cHL and to…
- Trial name
- NCT05140382
- Testing
- AZD4573
- Where
- 27 sites in United States, Australia and 6 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Acute Myelogenous Leukemia, Lymphoid Leukemia
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Objectives: 1. To evaluate disease free survival after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies. 2.
- Conditions
- Acute Myelogenous Leukemia, Lymphoid Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma
- Trial name
- NCT00683046
- Testing
- Fludarabine, Melphalan, Stem cells
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- University of Chicago
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Primary Objective: Evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic…
- Trial name
- ISAKIDS (NCT03860844)
- Testing
- Isatuximab, Dexamethasone or equivalent, Fludarabine
- Where
- 41 sites in United States, Argentina and 14 more
- Volunteers
- 67 people
- Sponsor
- Sanofi
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00918333
- Testing
- panobinostat, everolimus, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Mayo Clinic
Peripheral T-Cell Lymphoma (PTCL)
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficacy, and pharmacokinetics of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTCL).
- Trial name
- NCT02953652
- Testing
- HBI-8000
- Where
- 23 sites in Japan, South Korea
- Volunteers
- 55 people
- Sponsor
- HUYABIO International, LLC.